Philip A. van Damme
Founder at Stichting Sanammad
Profile
Philip A.
van Damme is the founder who has founded Stichting Sanammad in 2009 and Sanammad Pharmaceuticals BV in 2014, where he holds the title of President & Director.
He was also a former Director, Chief Scientific & Medical Officer at AXIM Biotechnologies, Inc. from 2014 to 2020 and a former Director at CanChew Biotechnologies LLC from 2012 to 2013.
Dr. van Damme earned a doctorate degree from the University of Utrecht in 1983.
Philip A. van Damme active positions
| Companies | Position | Start |
|---|---|---|
| Stichting Sanammad | Founder | 01/01/2009 |
| Sanammad Pharmaceuticals BV | Founder | 01/01/2014 |
Former positions of Philip A. van Damme
| Companies | Position | End |
|---|---|---|
| AXIM BIOTECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 06/05/2020 |
CanChew Biotechnologies LLC
 CanChew Biotechnologies LLC Pharmaceuticals: OtherHealth Technology CanChew Biotech focuses on the treatment of pain and other medical disorders with the application of chewing gum based cannabis/cannabinoids medical products. The company targets on the R&D and execution of their clinical development plan and subsequently out licensing of their technology. The development focuses on the R&D of the formulation, production and the development of chewing gum based products in their respective fields e.g.: for the treatment of numerous diseases like pain, nausea and vomiting, anorexia, spasticity and various other symptoms. | Chief Tech/Sci/R&D Officer | - |
Training of Philip A. van Damme
| University of Utrecht | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| AXIM BIOTECHNOLOGIES, INC. | Health Technology |
| Private companies | 3 |
|---|---|
CanChew Biotechnologies LLC
CanChew Biotechnologies LLC Pharmaceuticals: OtherHealth Technology CanChew Biotech focuses on the treatment of pain and other medical disorders with the application of chewing gum based cannabis/cannabinoids medical products. The company targets on the R&D and execution of their clinical development plan and subsequently out licensing of their technology. The development focuses on the R&D of the formulation, production and the development of chewing gum based products in their respective fields e.g.: for the treatment of numerous diseases like pain, nausea and vomiting, anorexia, spasticity and various other symptoms. | Health Technology |
| Stichting Sanammad | Miscellaneous |
| Sanammad Pharmaceuticals BV |
- Stock Market
- Insiders
- Philip A. van Damme
